N@N

HYDERABAD, India--([ BUSINESS WIRE ])--Dr. Reddyas Laboratories (NYSE: RDY) announced today that it has launched Montelukast Sodium Oral Granules, a bioequivalent generic version of Singulair (montelukast sodium) oral granules in the US market on September, 26, 2012, following the approval by the United States Food& Drug Administration (USFDA) of Dr.Reddyas ANDA for Montelukast Sodium Oral Granules.

The Singulair Oral Granulesbrand had U.S. sales of approximately $61 million for the most recent twelve months ending July 2012 according to IMS Health*.

Dr. Reddyas Montelukast Sodium Oral Granules in 4 mg are available in unit dosage package of 30.

Disclaimer
This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

About Dr. Reddyas
Dr. Reddyas Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products a" Dr. Reddyas offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand. For more information, log on to: [ www.drreddys.com ]

Singulair is a registered trademarkof Merck Co.

*IMS National Sales Perspectives: Retail and Non-Retail MAT July 2012